Latest Post

World’s largest payer-industry partnership? A case against unilateral cost-containment efforts

World’s largest payer-industry partnership? A case against unilateral cost-containment efforts

Canada’s unprecedented “18 at 18%” national generic drug pricing agreement is set to save the healthcare system billions. On 1 April 2014, the Canadian Generic Pharmaceutical Association (CGPA) reached a three-year national agreement with the Council of the Federation, comprised of Canada’s provincial and territorial premiers, that will significantly impact the generic industry in Canada … Continue reading

Recent Posts

Pages

Enter your email address to follow this blog and receive notifications of new posts by email.

Download extract from IHS Flexible Pricing strategies multi client study
Drug Price Erosion Multi Client Study extract download

About This Blog

In this blog, our experts share regular insights on the global life sciences industry. Join us as we look at issues in healthcare policy, market access, pricing and reimbursement and R&D. Comments are welcome!
40 countries covered. Download a sample chapter on Brazil
Download a complimentary white paper on market-access risk ratings
Download a sample of the primary research and analysis on French P&R reform

Follow IHS Life Sciences on Twitter

Follow

Get every new post delivered to your Inbox.

Join 309 other followers